实验室自动化与筛选协会2015亚洲年会（SLAS2015）已过期
推荐参加：精益营销管理 Lean-Marketing Management

发票类型：增值税普通发票增值税专用发票

会议通知

时间地点
会议时间：2015年4月9-10日
会议

会议门票

会议场地：

会议日程
（最终日程以会议现场为准）

4月9日星期四
08:4509:00	SLAS Opening Remarks
09:00-09:45	Keynote 1: Going Fishing for Better Medicines Karl Barry Sharpless, Nobel Prize Laureate, W. M. Keck Professor of Chemistry, The Scripps Research Institute, California
09:45-12:45	Session 1: Leading Science for Small Molecules Drug Discovery Co-chairs: Jonathan Connick, Executive Director, Head External in Vitro Pharmacology. Site Head, EDDS and PCD China, Merck & Co Inc., Member of SLAS Asia Council Bin Li, R&D Director, AbbVie China R&D Center, Secretary of SLAS Asia Council
09:45-10:15	Topic tbc Xin Xie, SIMM
10:15-10:45	Phenotypic Drug Discovery and Target Deconvolution Jing Li, Director of Pharmacology; Department of Screening and Protein Science; Merck Research Laboratories (MRL)
10:45-11:15	Break in Exhibit Hall
11:15-11:45	Discovery of HIV Integrase Inhibitors John Wai, Vice President of Medicinal Chemistry, WuXi AppTec (Shanghai)
11:45-12:45	Panel Discussion：Leveraging Technology and Tools to Enable Drug Discovery Moderator: Jonathan Connick, Executive Director, Head External in Vitro Pharmacology. Site Head, EDDS and PCD China, Merck & Co., Inc., Member of SLAS Asia Council Panelist: Pharma – Jing Li, Director of Pharmacology; Department of Screening and Protein Science; Merck Research Laboratories (MRL) CRO - Xuehai Tan, CEO & President, HD Biosciences Co., Ltd. Technology Provider - Joe Gu, LST APAC VP GM, Perkin Elmer Academia – Jian Li / Xin Xie - tbc
12:45_14:30	Lunch in Exhibit Hall
12:45-14:30	Posters
13:30-14:15	Exhibitor Tutorial 1 Exhibitor Tutorial 2
14:30-17:00	Session 2: Natural Product Drug Discovery & Synthetic Biology Co-chairs: Bing Xie, Managing Director, Asia Pacific for Cisbio Bioassays, Member of SLAS Asia Council Mike Zhang, Associate Sales Director, Research, BD Biosciences, Member of SLAS Asia Council
14:30-15:00	Discovery of NITD609 as Antimalarial: From Natural Product-like Lead to Clinical Candidate Bin Zou, Senior Medicinal Chemist, Novartis Institute for Tropical Diseases (Singapore)
15:00-15:30	HTS Hits - Which Should You Discard, and Why? Jonathan Baell, Research Professor, Medicinal Chemistry, Monash Institute of Pharmaceutical Science
15:30-16:00	Break in Exhibit Hall
16:00-16:30
16:30-17:00	Anti-infectious Natural Products from Marine-derived Microbes Xueting Liu, Associate Professor , CAS Key Laboratory of Pathogenic Microbiology & Immunology
17:00-17:30	Topic tbc Hakim Djaballah - tbc
17:30-19:00	Reception
4月10日星期五 Biologics Innovation Group 2015 Annual Conference
08:45-09:00	Welcome Speech- Biologics Enabling Working Group Annual Conference Bill Jiang, Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University
09:00-09:45	Keynote 2 : Vaccine and Therapeutic Antibody for New Outbreak of Pathogen Fu Gao, Vice President, Beijing Institutes of Life Science, Chinese Academy of Sciences; Director, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology; Professor, University of Science and Technology of China
09:45-12:30	Session 3: The Scientific Frontier of Biological Discovery
Part I	Co-chairs: Ying Yang, Founder & CEO, LBD Life Sciences Ltd; Asia Council Chair, Society for Laboratory Automation and Screening (SLAS) Bill Jiang, Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University
09:45-10:15	Virus and Anti-Virus Drug Discovery Zihe Rao, Biophysicist & Structural Biologist; Professor & Former President, Nankai University; Academician, Chinese Academy of Sciences; President, Biophysical Society of China; President, International Union of Pure and Applied Biophysics (IUPAB)
10:15-10:45	Break in Exhibit Hall
Part II	Co-Chairs: Guang Yang, Vice Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University Mingqiang Zhang, Vice President, R&D for China Amgen
10:45-11:15	Systems Approach to Translational Medicine Genhong Cheng, Director, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences; Professor, Department of Microbiology, Immunology & Molecular Genetics, UCLA
11:15-11:45	Therapeutic Antibody Discovery and Lead Selection Yan Wu, Associate Director, Genentech
11:45-12:30	Feature Talk and Panel Discussion: Case Study-NIBS’s Technology Transfer and Commercialization of Scientific Findings Moderator: Chengbin Wu, CSO and President of R&D, Shanghai CP Guojian Pharmaceutical Co., Ltd. Speaker: Xiaodong Wang, Biochemist; Director & Investigator, National Institute of Biological Science, China; Member, National Academy of Sciences, USA Panelist: Mingqiang Zhang, Vice President of R&D for China Amgen Yajun Xu, President of Shangpharma Investment; Executive Vice President, Shanghai Chempartner Bill Jiang, Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University
12:30-14:00	Lunch in Exhibit Hall
12:30-14:00	Posters
13:15-14:00	Exhibitor Tutorial 3: Location: Nanjing Room, Level 5 Sponsored by Exhibitor Tutorial 4: Location：Suzhou Room, Level 5
14:00-17:30	Session 4: ADC - From Technology, Process, Discovery to Development(To be confirmed)
Part I	Co-chairs: Xueming Qian, Chairman & CEO, Mabspace Biosciences CO., LTD Yajun Xu, President of Shangpharma Investment; Executive Vice President, Shanghai Chempartner
14:00-14:30	Antibody-Drug Conjugates for Cancer Therapy: Strategies and Perspectives Weikang Tao, CSO, Hengrui Pharmaceutical R&D
14:30-15:00	Site Specific Conjugation: Improvement of ADC Homogeneity and Druggability Properties Bruce Nianhe Han, CSO, NewBio Therapeutics
15:00-15:30	R&D of Next-generation ADCs Based on LDC Technology Gang Qin, CEO, GeneQuantum Healthcare (Suzhou) Co., Ltd.
15:30-16:00	Biological Characterization of Antibody Drug Conjugates Mary Hu, CEO, Shanghai Miracogen Inc
16:00-16:30	Break in Exhibit Hall
Part II	Co-chairs: Zhenping Zhu, Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation (New York); President, Kadmon China Chengbin Wu, CSO and President of R&D, Shanghai CP Guojian Pharmaceutical Co., Ltd.
16:30-17:00	A New Generation of Antibody-drug Conjugates for the Targeted Treatment of Cancer Robert Yongxin Zhao, CEO & Chairman, Hangzhou DAC Biotech Co., Ltd.
17:00-17:30	Developing a Novel ADC for Global Market via Innovative Three-party Collaboration Chris Chen, Head of Biologics, Wuxi Apptec
17:30-17:45	Closing Remark (awarding)